Clostridium difficile infection a public health problem

Jadwiga Janina Bednarek


Clostridium difficile is a Gram-positive rod that produces spores that are commonly found in animals, humans and the environment. Asymptomatic carriage of Clostridium difficile occurs in 3 15% of healthy adult population and increases up to 20-30% in hospitalized patients [1,2]. The number of nosocomial and non-hospital infections caused by the Clostridium difficile is increasing. The number of relapses is also increasing. In older patients with multi-organism, the serious course of the disease is more and more often observed. Multi-organism and the associated necessity to apply therapeutic activities disturb the homeostasis of the intestinal microbiome. Important factors disturbing the balance, favoring the occurrence of diarrhea symptoms and Clostridium difficile infection are: pharmacotherapy (mainly antibiotics, steroids, proton pump inhibitors) and past inflammations and procedures of the gastrointestinal tract. Fast identification of a pathogen in a stool sample taken from a patient with diarrhea is of therapeutic and, above all, epidemiological significance. Awareness of the existing threat, the use of effective prevention and isolation of infected patients and effective decontamination of the hospital environment gives hope for reducing the incidence of CDI.


diarhoea, Clostridium difficile

Full Text:



Ozaki E., Kato H., Kita H., Karasawa T., Maegawa T., Koino Y., i wsp.: Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. J Med Microbiol 2004, 53, 167 72.

Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108: 478-498.

Murphy C, Vernon M, Cullen M: Intravenous immunoglobulin for resistant Clostridium difficile infection. Age and Aging 2006; 35: 85-86.

Hryniewicz W., Martirosian G., Ozorowski T.: Zakażenia Clostridium difficile. Diagnostyka, terapia, profilaktyka. Narodowy Program Ochrony Antybiotyków. Ministerstwo Zdrowia, Warszawa 2011, dostępne online: difficile v6_10.pdf.

Ziółkowski G, Ziółkowska B, Ochocka B i wsp. Infekcje Clostridium difficile, niedoceniane zakażenia w aspekcie klinicznym i epidemiologicznym. Polskie Stowarzyszenie Pielęgniarek Epidemiologicznych, Katowice 2012.

Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013, 108: 478-498.

Pépin J., Valiquette L., Alary M.E. i wsp. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466–472.

Taylor G, Gravel D, Matlow A, Embree J, LeSaux N, Johnston L, Suh K, John M, Embil J, Henderson E, Roth V, Wong A. Assessing the magnitude and trends in hospital acquired infections in Canadian hospitals through sequential point prevalence surveys. Antimicrobial Resistance and Infection Control 2016; 5: 19.

Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009; 7: 526–536.

Magill SS, Edwards JR, Bamberg W, Beldavs Z, Dumyati G, Kainer M, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, Ray S, Thompson D, Wilson L, Fridkin S. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370: 1198-208.

Bauer M, Notermans D, van Benthem B, Brazier J, Wilcox M, Rupnik M, Monnet D, van Dissel J, Kuijper E. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011; 377: 63-73.

Krutova M, Matejkova J, Drevinek P, Kuijper E, Nyc O. Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015. European Society of Clinical Microbiology 2017; 36: 2251-2258.

Deptuła A, Trejnowska E, Ozorowski T i wsp. Badanie Punktowe Zakażeń Związanych z Opieką Zdrowotną i Stosowania Antybiotyków w Szpitalach Pracujących w Systemie Ostrego Dyżuru (PPS HAI&AU) w Polsce Raport z badania prowadzonego w latach 2014-2015. Warszawa 2016.

Wałaszek M, Wolak Z, Dobroś W. Prevalence of gastrointestinal system infections acquired in provincial hospital in 2004-2013. Przegl Epidemiol. 2014; 68: 661-668.

Cohen S, Gerding D, Johnson S. Kelly C, Loo V, Mc Donald L, Pepin J, Wilkox M. Wytyczne postępowania w zakażeniach Clostridium difficile wg SHEA i IDSA z komentarzem i aktualizacją ekspertów SHL 2012. Autorzy komentarza. Dulny G, Grzesiowski P, Gałdzińska-Adamczyk M. Stowarzyszenie Higieny Lecznictwa 2012.

Lynch SV, Pedersen O. The Human Intestinal Microbiome in Health and Disease. N Engl J Med 2016 ; 375: 2369-2379.

Elixhauser A, Steiner C, Gould C. Readmissions following Hospitalizations with Clostridium difficile nfections, 2009. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD). Agency for Health Care Policy and Research (US) 2006-2012. – [2018.03.13]

Mięgoć H, Łucejko M, Flisiak R. Przyczyny zakażeń Clostridium difficile - czy tylko antybiotykoterapia. Zakażenia. 2013; 13: 34-41.

Kelly C.P., Lamont J.T. Antibiotic-associated Diarrhea, Pseudomembranous Enterocolitis, and Clostridium difficile-Associated Diarrhea and Colitis w Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. W: Feldman M., Friedman L.S., Brandt L.J. (red.). Pathophysiology, Diagnosis, Management. 9th Edition, Mosby Elsevier, Philadelphia 2011; 1889–1903.

Kotowska M., Albrecht P., Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol. Ther. 2005; 21: 583–590.

Thomas C., Stevenson M., Riley T.V. Antibiotics and hospitalacquired Clostridium difficile-associated diarrhea: a systematic review. J. Antimicrob. Chemother. 2003; 51: 1339–1350.

Trifan A, Girleanu I, Stanciu C, Miftode E, Cojocariu C, Singeap AM, Sfarti C, Chiriac S, Cuciureanu, Stoica O. Clostridium difficile infection in hospitalized octogenarian patients. Geriatr Gerontol Int. Epub 2017 Nov 15. - [2018.07.05].

Lorden A.L, Jiang L, Radcliff T, Kelly K, Ohsfeldt L. Potentially Preventable Hospitalizations and the Burden of Healthcare-Associated Infections. Health services research and managerial epidemiology. - [2018.09.10].

Mertz D, Frei R, Plagge H, Battegay M, Widmer A. Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only, Eur J Clin Microbiol Infect Dis. 2010; 29: 1578-1578.

Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pomp inhibitors as a risk factor for Clostridium difficile associated in hospital patients. Am J Gastroenterol 2008; 103: 2308-2313.

National Clostridium difficile Standards Grope. Report to the Department of Health. J Hosp Infect. 2004; 56: 1-38.

Dulny G, Zalewska M, Młynarczyk G. Analiza stosowania antybiotyków jako czynnika ryzyka zakażeń Clostridium difficile. Forum zakażeń. 2013; 4: 223-228.

Lewis P, Lundberg T, Tharp J, Runnels C. Implementation of Global Strategies to Prevent Hospital-Onset Clostridium difficile Infection: Targeting Proton Pump Inhibitors and Probiotics. Annals of Pharmacotherapy 2017; 51: 848-854.

Ziółkowski G, Ziółkowska B, Malara M. Clostridium difficile – problem kliniczny i epidemiologiczny. Forum zakażeń. 2013; 4: 235-240.

Nathanson B, Higgins T, McGee W. The dangers of extreme body mass index values in patients with Clostridium difficile. Infection 2017: 45; 787-793.

Eyre D.W., Walker A.S., Wyllie D. i wsp. Infections in Oxfordshire Research Database Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin. Infect. Dis. 2012; 55 (supl. 2): S77–S87

Alcalá L., Martín A., Marín M. i wsp. Spanish Clostridium difficile Study Group. The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin. Microbiol. Infect. 2012; 18: E204–E213.

Bauer M, Kuijper E, van Dissel J. European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 2009; 15: 1067-1079.

Davies K, Longshaw C, Davis G, Bouza E, Barbut F, Barna Z, Delmee M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei I, Mentula S, Mastrantonio P, von Muller L, Oleastro M, Petinaki E, Pituch H, Noren T, Novakova E, Nyc O, Rupnik M, Schmid D, Wilcox M. Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis. 2014; 14:1208-19.

Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 2005; 5: 549–557

McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg. Infect. Dis. 2006; 12: 409–415

National Clostridium difficile Standards Group. Report to the Department of Health. J. Hosp. Infect. 2004; 56 (supl.1): 1–38

Doh YS, Kim YS, Jung HJ et al. Long-term clinical outcome of Clostridium difficile infection in hospitalized patients: a single center study. Intest Res 2014;12(4):299–305.

Pituch H, van Leeuwen W, Maquelin K ad all. Toxin profiles and resistances to macrolides and newer fluoroquinolones as epidemicity determinants of clinical isolates of Clostridium difficile from Warsaw, Poland. J Clin Microbiol 2007; 1607-10.

Wultańska D, Obuch-Woszczatyński P, Pituch H, Łuczak M. Przegląd wrażliwości klinicznych szczegółów clostridium difficile izolowanych z przewodu pokarmowego dzieci hospitalizowanych w oddziałach pediatrycznych w Warszawie na leki stosowane w lecznictwie szpitalnym. Med Dośw Mikrobiol 2007; 59: 161-168.

Rydzewska G. Fidaksomycyna w leczeniu zakażeń clostridium difficile. Forum zakażeń 2016;7(2):93–96

Bauer M.P., Kuijper E.J., van Dissel J.T; European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin. Microbiol. Infect. 2009; 15: 1067–1079.

Cohen S.H., Gerding D.N., Johnson S. i wsp.; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control. Hosp. Epidemiol. 2010; 31: 431–455.

Cielecka-Piontek J, Rajska-Neumann A, Wieczorowska-Tobis A. Wielolekowość w populacji geriatrycznej. Nowiny Lekarskie 2006: 75; 13-17.



  • There are currently no refbacks.

Copyright (c) 2018 © The Authors

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski